OptimizeRx Corporation (OPRX)

Over the past six months, OptimizeRx Corp.'s stock (OPRX) has experienced a 52-week high of $22.25 and a 52-week low of $3.99. As of February 5, 2026, the stock price was in the range of $10.56 to $10.89. Key events include strong Q3 2025 earnings with increased revenue and improved gross margin, as well as raised 2025 revenue guidance after Q2 2025 earnings. Analyst ratings and price targets were updated, with some firms increasing their price targets. OptimizeRx's focus on AI and workflow integration was highlighted. A 33% share price plunge was noted in November 2025, and several officers and directors engaged in selling company stock. OptimizeRx is scheduled to host a conference call on March 5, 2026, to discuss its fourth quarter and full year 2025 financial results.

While specific demand seasonality is not detailed, OptimizeRx aims to reduce business cyclicality by transitioning its Dynamic Audience Activation Platform (DAAP) customers to a subscription-based model. This suggests that the company's current business model may experience some level of seasonality or unpredictability in demand, which they are actively working to mitigate.

OptimizeRx Corp. is a digital health company connecting pharmaceutical companies and healthcare providers through its digital health network. It operates in the Healthcare sector, specifically Health Care Technology. OptimizeRx offers EHR workflow solutions, including financial messaging, patient education, and brand messaging. Its products include the Dynamic Audience Activation Platform (DAAP), Micro-Neighborhood Targeting, and Profiler. The company also provides banner messages and media execution solutions across a consumer omnichannel network. Founded in 2006 and headquartered in Waltham, Massachusetts, OptimizeRx has 129 employees and a subsidiary, Medicx, in Scottsdale, Arizona.

OptimizeRx Corp. primarily operates across the United States, partnering with EHR vendors and health systems. Its network reaches tens of thousands of healthcare providers. The company's headquarters are in Waltham, Massachusetts, and its subsidiary Medicx is based in Scottsdale, Arizona.

OptimizeRx Corp. has maintained a generally positive brand reputation, particularly concerning its operational performance and strategic direction. The company received a "Low Risk" ESG rating. Analysts have largely rated OPRX as "Very Bullish" or "Market Outperform." The company's Q3 2025 earnings contributed positively to its reputation. While there was a notable "33% Share Price Plunge" in November 2025, this event primarily impacted stock performance rather than directly damaging the company's brand reputation.

OptimizeRx Corporation has a diverse ownership structure, with 234 institutional owners and shareholders holding a total of 15,476,864 shares. Major institutional owners include Whetstone Capital Advisors, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual insiders collectively own 15.3% of the company, accounting for 2,854,279 shares.